Table 2 Clinical characteristics and treatments in patients with moderate to severe UC exacerbations.

From: The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort

Characteristics

Overall exacerbations

Initial exacerbations

Relapse exacerbations

(n = 959)

(n = 525)

(n = 266)

Age, year, mean (SD)

38.6 (17.4)

38.1 (17.9)

38.3 (16.9)

Partial Mayo, severe (n [%])

246 (25.6)

155 (29.5)

59 (22.2)

Pancolitis UC (n [%])

403 (42.0)

210 (40.0)

115 (43.2)

Laboratory data, mean (SD)

White blood cell

8924.8 (3769.8)

9201.2 (3891.9)

8736.7 (3637.8)

Serum albumin

3.76 (0.71)

3.61 (0.79)

3.99 (0.532)

C-reactive protein

2.70 (4.36)

3.23 (4.83)

2.06 (3.42)

Hospitalization (n [%])

372 (38.8)

236 (45.0)

85 (31.7)

Treatments for exacerbations (n [%])

5-ASAs

330 (34.4)

292 (55.6)

29 (10.9)

Single-use

124 (12.9)

106 (20.2)

15 (5.6) 

Corticosteroids

628 (65.5)

342 (65.1)

179 (67.2)

Immunomodulators

78 (8.1)

39 (7.4)

20 (7.5)

Calcineurin inhibitors

204 (21.3)

110 (21.0)

61 (22.9)

Biologics

164 (17.1)

55 (10.5)

41 (15.4)

Apheresis

254 (26.5)

133 (25.3)

78 (29.3)

Surgical resection

81 (8.4)

42 (8.0)

22 (8.3)